| Literature DB >> 31852482 |
Kasper Yde Jensen1,2,3, Mikkel Jacobsen1,4,2, Henrik Daa Schrøder2,5, Per Aagaard1, Jakob Lindberg Nielsen1, Anders Nørkær Jørgensen1,5, Eleanor Boyle6, Rune Dueholm Bech7, Sofie Rosmark4, Louise Pyndt Diederichsen8,9, Ulrik Frandsen1.
Abstract
BACKGROUND: Sporadic inclusion body myositis (sIBM) is clinically characterised by progressive proximal and distal muscle weakness and impaired physical function while skeletal muscle tissue displays abnormal cellular infiltration of T cells, macrophages, and dendritic cells. Only limited knowledge exists about the effects of low-load blood flow restriction exercise in sIBM patients, and its effect on the immunological responses at the myocellular level remains unknown. The present study is the first to investigate the longitudinal effects of low-load blood flow restriction exercise on innate and adaptive immune markers in skeletal muscle from sIBM patients.Entities:
Keywords: Blood flow restriction exercise; Disease progression; Inflammation; Macrophages; Sporadic inclusion body myositis; T cells; T lymphocytes
Mesh:
Substances:
Year: 2019 PMID: 31852482 PMCID: PMC6921522 DOI: 10.1186/s13075-019-2036-2
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Baseline characteristics of included patients. BMI body mass index, MMT8 manual muscle testing 8
| Age | Gender | BMI | Months from diagnosis | Creatine kinase | Health assessment questionnaire | MMT8 | Immunosuppressive medicine | |
|---|---|---|---|---|---|---|---|---|
| BFRE ( | ||||||||
| Mean | 67.5 | W/M: 3/8 | 24.71 | 57.8 | 549 | 0.85 | 69.6 | 4/11 |
| SD | 6.5 | 3.19 | 87.7 | 397 | 0.83 | 6.2 | ||
| Control ( | ||||||||
| Mean | 69.2 | W/M: 2/8 | 24.69 | 46.6 | 308 | 1.125 | 67.9 | 2/10 |
| SD | 4.6 | 4.68 | 27.2 | 247 | 0.88 | 6.0 | ||
Fig. 1Flowchart of included patients (original BFRE and control). Post control, patients from the control who underwent the BFRE training intervention after the 12-week control period
Overview of antibodies and incubation times
| Antibody | Origin | Target | Company | Catalogue number | Dilution | Incubation |
|---|---|---|---|---|---|---|
| CD3 | Rabbit | T cells | Dako/Agilent | A0452 | 1:2000 | Overnight |
| CD8 | Mouse | T cells and NK | Dako/Agilent | M7103 | 1:100 | Overnight |
| CD68 | Mouse | CD68+ macrophages | DakoCytomation | M0814 | 1:400 | Overnight |
| CD206 (MMR) | Goat | CD 206+ macrophages | DakoCytomation | AF2534 | 1:400 | Overnight |
| CD244 | Goat | CD28null T cells | R&D Systems | AF1039 | 1:100 | Overnight |
| DAPI | DNA | Thermo Fisher | 62248 | 1:10000 | 10 s | |
| FoxP3 | Mouse | Treg cells | Thermo Fisher | 11-4777-82 | 1:500 | Overnight |
| Laminin | Rabbit | Basal membrane | DakoCytomation | Z0097 | 1:2000 | Overnight |
| MHC—fast | Mouse | Type 2 fibres | Sigma-Aldrich | M4276 | 1:1000 | 30 min |
Fig. 2Representative immunohistochemical staining. a CD-68. b CD-206. c MHC-Fast. d Nuclei/DAPI. e Merged
Fig. 3a Graph depicting amount of total CD3+ T cells. b Graph depicting amount of CD3+/CD8+ cytotoxic T cells. c Graph depecting amount of CD28null T-cells. d Graph depicting amount of FOXP3+ T regulatory. e Graph depicting amount of CD68+/CD206− M1 macrophages. f Graph depicting amount of CD68+/CD206+ M2 macrophages. g Graph depicting amount of CD3−/CD8+ natural killer cells. Triangles show the pre and post for each patient in the intervention group (n = 11). Circles show the pre and post for each patient in the control group (n = 10). Bars show group mean. Asterisk signifies a significant change from pre to post (p ≤ 0.05). All graphs are shown in cells/mm2
Fig. 4a Overview of a T cell staining CD-3 (green), CD-8 (red) and nuclei (Blue). See b for a macrophage staining of the same area. b Overview of a macrophage staining CD-68 (green), CD-206 (yellow), MHC Fast (red) and Nuclei (blue). See a for a T cell staining of the same area. c Close up comparison of the same area showing overlapping macrophage and T cell staining around small-sized type 2 fibres. (A) Macrophage staining, with CD-68 (green), CD-206 (yellow), MHC Fast (red) and Nuclei (blue). (B) T cell staining, with CD-3 (green), CD-8 (red) and Nuclei (blue)
Responders vs. non-responders to BFRE training. Responders, patients showing progress in all three tests of functional capacity (FP22, FP15); non-responders, patients with a decline in at least two of the tests of functional capacity (FP3, FP14, FP20). An upregulation (positive response) is defined as a 10% increase or more. A decline (negative response) is defined as 10% decrease or more. No change is defined as a change of less than 10%
| Patient | T cells (CD3+) | Cytotoxic T cells (CD3+ CD8+) | CD28null T cells (CD3+ CD244+) | Cytotoxic T cell subset (CD8+ CD244+) | M1 macrophages (CD68+ CD206−) | M2 macrophages (CD68+ CD206+) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Change | Pre | Post | Change | Pre | Post | Change | Pre | Post | Change | Pre | Post | Change | Pre | Post | Change | |
| FP 22 | 1689 | 841 | ↓ | 452 | 24 | ↓ | 10 | 18 | ↑ | 74 | 67 | ↔ | 198 | 142 | ↓ | 326 | 305 | ↔ |
| FP 15 | 115 | 29 | ↓ | 31 | 4 | ↓ | 10 | 10 | ↔ | 15 | 6 | ↓ | 98 | 44 | ↓ | 106 | 15 | ↓ |
| FP 3 | 103 | 243 | ↑ | 22 | 60 | ↑ | 9 | 18 | ↑ | 14 | 51 | ↑ | 67 | 60 | ↓ | 67 | 73 | ↔ |
| FP 14 | 3 | 4 | ↑ | 0.4 | 0.0 | ↓ | 3 | 13 | ↑ | 6 | 9 | ↑ | 13 | 39 | ↑ | 3 | 20 | ↑ |
| FP 20 | 10 | 29 | ↑ | 3 | 6 | ↑ | 16 | 32 | ↑ | 10 | 11 | ↔ | 49 | 53 | ↔ | 6 | 27 | ↑ |